http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 23 Jul 2026 08:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Cryoport+to+Report+Second+Quarter+2026+Financial+Results+on+August+6%2C+2026/26804862.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>July 23, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4737439-1&amp;h=3709863143&amp;u=https%3A%2F%2Fcryoportinc.com%2F&amp;a=Cryoport%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport, Inc.</span></a> (Nasdaq: CYRX) ("<span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport</span>" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the second quarter ended <chron>June 30, 2026</chron> on <chron>Thursday, August 6, 2026</chron> after <location value="LC/us" idsrc="xmltag.org" >U.S</location>. markets close.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Cryoport+to+Report+Second+Quarter+2026+Financial+Results+on+August+6%2C+2026/26804862.html Thu, 23 Jul 2026 08:00:00 -0400 CYRX O.01522978 http://www.streetinsider.com/Press+Releases/Cryoport+to+Report+Second+Quarter+2026+Financial+Results+on+August+6%2C+2026/26804862.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>July 23, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4737439-1&amp;h=3709863143&amp;u=https%3A%2F%2Fcryoportinc.com%2F&amp;a=Cryoport%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport, Inc.</span></a> (Nasdaq: CYRX) ("<span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport</span>" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the second quarter ended <chron>June 30, 2026</chron> on <chron>Thursday, August 6, 2026</chron> after <location value="LC/us" idsrc="xmltag.org" >U.S</location>. markets close.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Cryoport+to+Report+Second+Quarter+2026+Financial+Results+on+August+6%2C+2026/26804862.html Thu, 23 Jul 2026 08:00:00 -0400 CYRX O.01522978 http://www.streetinsider.com/PRNewswire/Cryoport+to+Report+Second+Quarter+2026+Financial+Results+on+August+6%2C+2026/26804862.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>July 23, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4737439-1&amp;h=3709863143&amp;u=https%3A%2F%2Fcryoportinc.com%2F&amp;a=Cryoport%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport, Inc.</span></a> (Nasdaq: CYRX) ("<span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport</span>" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the second quarter ended <chron>June 30, 2026</chron> on <chron>Thursday, August 6, 2026</chron> after <location value="LC/us" idsrc="xmltag.org" >U.S</location>. markets close.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Cryoport+to+Report+Second+Quarter+2026+Financial+Results+on+August+6%2C+2026/26804862.html Thu, 23 Jul 2026 08:00:00 -0400 CYRX O.01522978 http://www.streetinsider.com/PRNewswire/Cryoport+to+Report+Second+Quarter+2026+Financial+Results+on+August+6%2C+2026/26804862.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>July 23, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4737439-1&amp;h=3709863143&amp;u=https%3A%2F%2Fcryoportinc.com%2F&amp;a=Cryoport%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport, Inc.</span></a> (Nasdaq: CYRX) ("<span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport</span>" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the second quarter ended <chron>June 30, 2026</chron> on <chron>Thursday, August 6, 2026</chron> after <location value="LC/us" idsrc="xmltag.org" >U.S</location>. markets close.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Cryoport+to+Report+Second+Quarter+2026+Financial+Results+on+August+6%2C+2026/26804862.html Thu, 23 Jul 2026 08:00:00 -0400 CYRX O.01522978 http://www.streetinsider.com/Corporate+News/Cryoport+wins+cryopreservation+contract+for+Verismo+CAR+T+trials/26688544.html <p>Cryoport, Inc. (NASDAQ: CYRX) announced that its IntegriCell cryopreservation services have been selected by Verismo Therapeutics to support two clinical-stage CAR T cell therapy programs.</p><p>Verismo, a subsidiary of HLB Innovation, is developing a multi-chain KIR-CAR platform for the treatment of solid tumors and B cell-associated disorders. Its two lead candidates, SynKIR-110 and SynKIR-310, are currently being evaluated in separate Phase 1 clinical trials. Initial Phase 1 data for both candidates were presented at the American Association for Cancer Research Annual Meeting in 2026.</p><p>SynKIR-110 is being evaluated in the STAR-101 Phase 1 trial in patients with advanced mesothelin-expressing solid tumors. SynKIR-310 http://www.streetinsider.com/Corporate+News/Cryoport+wins+cryopreservation+contract+for+Verismo+CAR+T+trials/26688544.html Thu, 25 Jun 2026 08:01:47 -0400 CYRX http://www.streetinsider.com/FDA/Cryoport+wins+cryopreservation+contract+for+Verismo+CAR+T+trials/26688544.html <p>Cryoport, Inc. (NASDAQ: CYRX) announced that its IntegriCell cryopreservation services have been selected by Verismo Therapeutics to support two clinical-stage CAR T cell therapy programs.</p><p>Verismo, a subsidiary of HLB Innovation, is developing a multi-chain KIR-CAR platform for the treatment of solid tumors and B cell-associated disorders. Its two lead candidates, SynKIR-110 and SynKIR-310, are currently being evaluated in separate Phase 1 clinical trials. Initial Phase 1 data for both candidates were presented at the American Association for Cancer Research Annual Meeting in 2026.</p><p>SynKIR-110 is being evaluated in the STAR-101 Phase 1 trial in patients with advanced mesothelin-expressing solid tumors. SynKIR-310 http://www.streetinsider.com/FDA/Cryoport+wins+cryopreservation+contract+for+Verismo+CAR+T+trials/26688544.html Thu, 25 Jun 2026 08:01:47 -0400 CYRX http://www.streetinsider.com/Press+Releases/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html <div class="xn-content"> <p class="prntac"><i>IntegriCell Provides Process Development, <span value="ACORN:3116858326" idsrc="xmltag.org" >Technology Transfer</span>, and Clinical Cryopreservation Services Supporting Verismo's Novel Multi-chain KIR-CAR Programs for Lead Candidates SynKIR™-110 and SynKIR™-310</i></p><p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>June 25, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=1388779963&amp;u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4679950-1%26h%3D3790823054%26u%3Dhttps%253A%252F%252Fcryoportinc.com%252F%26a%3DCryoport%252C%2BInc.&amp;a=Cryoport%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport, Inc.</span></a> (NASDAQ: CYRX) ("<span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport</span>" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that <span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport Systems'</span> IntegriCell^® cryopreservation services have been selected by <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=3704306897&amp;u=https%3A%2F%2Fverismotherapeutics.com%2F&amp;a=Verismo+Therapeutics" target="_blank" rel="nofollow"><span value="ACORN:5021694617" idsrc="xmltag.org" >Verismo Therapeutics</span></a>, a clinical-stage CAR T cell therapy http://www.streetinsider.com/Press+Releases/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html Thu, 25 Jun 2026 08:00:00 -0400 A.31168583 A.35552990 A.39531742 A.50216946 CYRX O.00074346 O.01522978 O.20222297 O.22023464 O.57762027 http://www.streetinsider.com/Press+Releases/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html <div class="xn-content"> <p class="prntac"><i>IntegriCell Provides Process Development, <span value="ACORN:3116858326" idsrc="xmltag.org" >Technology Transfer</span>, and Clinical Cryopreservation Services Supporting Verismo's Novel Multi-chain KIR-CAR Programs for Lead Candidates SynKIR™-110 and SynKIR™-310</i></p><p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>June 25, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=1388779963&amp;u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4679950-1%26h%3D3790823054%26u%3Dhttps%253A%252F%252Fcryoportinc.com%252F%26a%3DCryoport%252C%2BInc.&amp;a=Cryoport%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport, Inc.</span></a> (NASDAQ: CYRX) ("<span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport</span>" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that <span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport Systems'</span> IntegriCell^® cryopreservation services have been selected by <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=3704306897&amp;u=https%3A%2F%2Fverismotherapeutics.com%2F&amp;a=Verismo+Therapeutics" target="_blank" rel="nofollow"><span value="ACORN:5021694617" idsrc="xmltag.org" >Verismo Therapeutics</span></a>, a clinical-stage CAR T cell therapy http://www.streetinsider.com/Press+Releases/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html Thu, 25 Jun 2026 08:00:00 -0400 A.31168583 A.35552990 A.39531742 A.50216946 CYRX O.00074346 O.01522978 O.20222297 O.22023464 O.57762027 http://www.streetinsider.com/Press+Releases/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html <div class="xn-content"> <p class="prntac"><i>IntegriCell Provides Process Development, <span value="ACORN:3116858326" idsrc="xmltag.org" >Technology Transfer</span>, and Clinical Cryopreservation Services Supporting Verismo's Novel Multi-chain KIR-CAR Programs for Lead Candidates SynKIR™-110 and SynKIR™-310</i></p><p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>June 25, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=1388779963&amp;u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4679950-1%26h%3D3790823054%26u%3Dhttps%253A%252F%252Fcryoportinc.com%252F%26a%3DCryoport%252C%2BInc.&amp;a=Cryoport%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport, Inc.</span></a> (NASDAQ: CYRX) ("<span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport</span>" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that <span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport Systems'</span> IntegriCell^® cryopreservation services have been selected by <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=3704306897&amp;u=https%3A%2F%2Fverismotherapeutics.com%2F&amp;a=Verismo+Therapeutics" target="_blank" rel="nofollow"><span value="ACORN:5021694617" idsrc="xmltag.org" >Verismo Therapeutics</span></a>, a clinical-stage CAR T cell therapy http://www.streetinsider.com/Press+Releases/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html Thu, 25 Jun 2026 08:00:00 -0400 A.31168583 A.35552990 A.39531742 A.50216946 CYRX O.00074346 O.01522978 O.20222297 O.22023464 O.57762027 http://www.streetinsider.com/Press+Releases/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html <div class="xn-content"> <p class="prntac"><i>IntegriCell Provides Process Development, <span value="ACORN:3116858326" idsrc="xmltag.org" >Technology Transfer</span>, and Clinical Cryopreservation Services Supporting Verismo's Novel Multi-chain KIR-CAR Programs for Lead Candidates SynKIR™-110 and SynKIR™-310</i></p><p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>June 25, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=1388779963&amp;u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4679950-1%26h%3D3790823054%26u%3Dhttps%253A%252F%252Fcryoportinc.com%252F%26a%3DCryoport%252C%2BInc.&amp;a=Cryoport%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport, Inc.</span></a> (NASDAQ: CYRX) ("<span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport</span>" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that <span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport Systems'</span> IntegriCell^® cryopreservation services have been selected by <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=3704306897&amp;u=https%3A%2F%2Fverismotherapeutics.com%2F&amp;a=Verismo+Therapeutics" target="_blank" rel="nofollow"><span value="ACORN:5021694617" idsrc="xmltag.org" >Verismo Therapeutics</span></a>, a clinical-stage CAR T cell therapy http://www.streetinsider.com/Press+Releases/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html Thu, 25 Jun 2026 08:00:00 -0400 A.31168583 A.35552990 A.39531742 A.50216946 CYRX O.00074346 O.01522978 O.20222297 O.22023464 O.57762027 http://www.streetinsider.com/Press+Releases/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html <div class="xn-content"> <p class="prntac"><i>IntegriCell Provides Process Development, <span value="ACORN:3116858326" idsrc="xmltag.org" >Technology Transfer</span>, and Clinical Cryopreservation Services Supporting Verismo's Novel Multi-chain KIR-CAR Programs for Lead Candidates SynKIR™-110 and SynKIR™-310</i></p><p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>June 25, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=1388779963&amp;u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4679950-1%26h%3D3790823054%26u%3Dhttps%253A%252F%252Fcryoportinc.com%252F%26a%3DCryoport%252C%2BInc.&amp;a=Cryoport%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport, Inc.</span></a> (NASDAQ: CYRX) ("<span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport</span>" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that <span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport Systems'</span> IntegriCell^® cryopreservation services have been selected by <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=3704306897&amp;u=https%3A%2F%2Fverismotherapeutics.com%2F&amp;a=Verismo+Therapeutics" target="_blank" rel="nofollow"><span value="ACORN:5021694617" idsrc="xmltag.org" >Verismo Therapeutics</span></a>, a clinical-stage CAR T cell therapy http://www.streetinsider.com/Press+Releases/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html Thu, 25 Jun 2026 08:00:00 -0400 A.31168583 A.35552990 A.39531742 A.50216946 CYRX O.00074346 O.01522978 O.20222297 O.22023464 O.57762027 http://www.streetinsider.com/Press+Releases/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html <div class="xn-content"> <p class="prntac"><i>IntegriCell Provides Process Development, <span value="ACORN:3116858326" idsrc="xmltag.org" >Technology Transfer</span>, and Clinical Cryopreservation Services Supporting Verismo's Novel Multi-chain KIR-CAR Programs for Lead Candidates SynKIR™-110 and SynKIR™-310</i></p><p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>June 25, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=1388779963&amp;u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4679950-1%26h%3D3790823054%26u%3Dhttps%253A%252F%252Fcryoportinc.com%252F%26a%3DCryoport%252C%2BInc.&amp;a=Cryoport%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport, Inc.</span></a> (NASDAQ: CYRX) ("<span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport</span>" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that <span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport Systems'</span> IntegriCell^® cryopreservation services have been selected by <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=3704306897&amp;u=https%3A%2F%2Fverismotherapeutics.com%2F&amp;a=Verismo+Therapeutics" target="_blank" rel="nofollow"><span value="ACORN:5021694617" idsrc="xmltag.org" >Verismo Therapeutics</span></a>, a clinical-stage CAR T cell therapy http://www.streetinsider.com/Press+Releases/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html Thu, 25 Jun 2026 08:00:00 -0400 A.31168583 A.35552990 A.39531742 A.50216946 CYRX O.00074346 O.01522978 O.20222297 O.22023464 O.57762027 http://www.streetinsider.com/Press+Releases/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html <div class="xn-content"> <p class="prntac"><i>IntegriCell Provides Process Development, <span value="ACORN:3116858326" idsrc="xmltag.org" >Technology Transfer</span>, and Clinical Cryopreservation Services Supporting Verismo's Novel Multi-chain KIR-CAR Programs for Lead Candidates SynKIR™-110 and SynKIR™-310</i></p><p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>June 25, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=1388779963&amp;u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4679950-1%26h%3D3790823054%26u%3Dhttps%253A%252F%252Fcryoportinc.com%252F%26a%3DCryoport%252C%2BInc.&amp;a=Cryoport%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport, Inc.</span></a> (NASDAQ: CYRX) ("<span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport</span>" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that <span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport Systems'</span> IntegriCell^® cryopreservation services have been selected by <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=3704306897&amp;u=https%3A%2F%2Fverismotherapeutics.com%2F&amp;a=Verismo+Therapeutics" target="_blank" rel="nofollow"><span value="ACORN:5021694617" idsrc="xmltag.org" >Verismo Therapeutics</span></a>, a clinical-stage CAR T cell therapy http://www.streetinsider.com/Press+Releases/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html Thu, 25 Jun 2026 08:00:00 -0400 A.31168583 A.35552990 A.39531742 A.50216946 CYRX O.00074346 O.01522978 O.20222297 O.22023464 O.57762027 http://www.streetinsider.com/Press+Releases/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html <div class="xn-content"> <p class="prntac"><i>IntegriCell Provides Process Development, <span value="ACORN:3116858326" idsrc="xmltag.org" >Technology Transfer</span>, and Clinical Cryopreservation Services Supporting Verismo's Novel Multi-chain KIR-CAR Programs for Lead Candidates SynKIR™-110 and SynKIR™-310</i></p><p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>June 25, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=1388779963&amp;u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4679950-1%26h%3D3790823054%26u%3Dhttps%253A%252F%252Fcryoportinc.com%252F%26a%3DCryoport%252C%2BInc.&amp;a=Cryoport%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport, Inc.</span></a> (NASDAQ: CYRX) ("<span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport</span>" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that <span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport Systems'</span> IntegriCell^® cryopreservation services have been selected by <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=3704306897&amp;u=https%3A%2F%2Fverismotherapeutics.com%2F&amp;a=Verismo+Therapeutics" target="_blank" rel="nofollow"><span value="ACORN:5021694617" idsrc="xmltag.org" >Verismo Therapeutics</span></a>, a clinical-stage CAR T cell therapy http://www.streetinsider.com/Press+Releases/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html Thu, 25 Jun 2026 08:00:00 -0400 A.31168583 A.35552990 A.39531742 A.50216946 CYRX O.00074346 O.01522978 O.20222297 O.22023464 O.57762027 http://www.streetinsider.com/Press+Releases/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html <div class="xn-content"> <p class="prntac"><i>IntegriCell Provides Process Development, <span value="ACORN:3116858326" idsrc="xmltag.org" >Technology Transfer</span>, and Clinical Cryopreservation Services Supporting Verismo's Novel Multi-chain KIR-CAR Programs for Lead Candidates SynKIR™-110 and SynKIR™-310</i></p><p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>June 25, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=1388779963&amp;u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4679950-1%26h%3D3790823054%26u%3Dhttps%253A%252F%252Fcryoportinc.com%252F%26a%3DCryoport%252C%2BInc.&amp;a=Cryoport%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport, Inc.</span></a> (NASDAQ: CYRX) ("<span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport</span>" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that <span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport Systems'</span> IntegriCell^® cryopreservation services have been selected by <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=3704306897&amp;u=https%3A%2F%2Fverismotherapeutics.com%2F&amp;a=Verismo+Therapeutics" target="_blank" rel="nofollow"><span value="ACORN:5021694617" idsrc="xmltag.org" >Verismo Therapeutics</span></a>, a clinical-stage CAR T cell therapy http://www.streetinsider.com/Press+Releases/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html Thu, 25 Jun 2026 08:00:00 -0400 A.31168583 A.35552990 A.39531742 A.50216946 CYRX O.00074346 O.01522978 O.20222297 O.22023464 O.57762027 http://www.streetinsider.com/Press+Releases/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html <div class="xn-content"> <p class="prntac"><i>IntegriCell Provides Process Development, <span value="ACORN:3116858326" idsrc="xmltag.org" >Technology Transfer</span>, and Clinical Cryopreservation Services Supporting Verismo's Novel Multi-chain KIR-CAR Programs for Lead Candidates SynKIR™-110 and SynKIR™-310</i></p><p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>June 25, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=1388779963&amp;u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4679950-1%26h%3D3790823054%26u%3Dhttps%253A%252F%252Fcryoportinc.com%252F%26a%3DCryoport%252C%2BInc.&amp;a=Cryoport%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport, Inc.</span></a> (NASDAQ: CYRX) ("<span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport</span>" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that <span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport Systems'</span> IntegriCell^® cryopreservation services have been selected by <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=3704306897&amp;u=https%3A%2F%2Fverismotherapeutics.com%2F&amp;a=Verismo+Therapeutics" target="_blank" rel="nofollow"><span value="ACORN:5021694617" idsrc="xmltag.org" >Verismo Therapeutics</span></a>, a clinical-stage CAR T cell therapy http://www.streetinsider.com/Press+Releases/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html Thu, 25 Jun 2026 08:00:00 -0400 A.31168583 A.35552990 A.39531742 A.50216946 CYRX O.00074346 O.01522978 O.20222297 O.22023464 O.57762027 http://www.streetinsider.com/PRNewswire/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html <div class="xn-content"> <p class="prntac"><i>IntegriCell Provides Process Development, <span value="ACORN:3116858326" idsrc="xmltag.org" >Technology Transfer</span>, and Clinical Cryopreservation Services Supporting Verismo's Novel Multi-chain KIR-CAR Programs for Lead Candidates SynKIR™-110 and SynKIR™-310</i></p><p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>June 25, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=1388779963&amp;u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4679950-1%26h%3D3790823054%26u%3Dhttps%253A%252F%252Fcryoportinc.com%252F%26a%3DCryoport%252C%2BInc.&amp;a=Cryoport%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport, Inc.</span></a> (NASDAQ: CYRX) ("<span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport</span>" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that <span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport Systems'</span> IntegriCell^® cryopreservation services have been selected by <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=3704306897&amp;u=https%3A%2F%2Fverismotherapeutics.com%2F&amp;a=Verismo+Therapeutics" target="_blank" rel="nofollow"><span value="ACORN:5021694617" idsrc="xmltag.org" >Verismo Therapeutics</span></a>, a clinical-stage CAR T cell therapy http://www.streetinsider.com/PRNewswire/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html Thu, 25 Jun 2026 08:00:00 -0400 A.31168583 A.35552990 A.39531742 A.50216946 CYRX O.00074346 O.01522978 O.20222297 O.22023464 O.57762027 http://www.streetinsider.com/PRNewswire/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html <div class="xn-content"> <p class="prntac"><i>IntegriCell Provides Process Development, <span value="ACORN:3116858326" idsrc="xmltag.org" >Technology Transfer</span>, and Clinical Cryopreservation Services Supporting Verismo's Novel Multi-chain KIR-CAR Programs for Lead Candidates SynKIR™-110 and SynKIR™-310</i></p><p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>June 25, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=1388779963&amp;u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4679950-1%26h%3D3790823054%26u%3Dhttps%253A%252F%252Fcryoportinc.com%252F%26a%3DCryoport%252C%2BInc.&amp;a=Cryoport%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport, Inc.</span></a> (NASDAQ: CYRX) ("<span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport</span>" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that <span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport Systems'</span> IntegriCell^® cryopreservation services have been selected by <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=3704306897&amp;u=https%3A%2F%2Fverismotherapeutics.com%2F&amp;a=Verismo+Therapeutics" target="_blank" rel="nofollow"><span value="ACORN:5021694617" idsrc="xmltag.org" >Verismo Therapeutics</span></a>, a clinical-stage CAR T cell therapy http://www.streetinsider.com/PRNewswire/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html Thu, 25 Jun 2026 08:00:00 -0400 A.31168583 A.35552990 A.39531742 A.50216946 CYRX O.00074346 O.01522978 O.20222297 O.22023464 O.57762027 http://www.streetinsider.com/PRNewswire/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html <div class="xn-content"> <p class="prntac"><i>IntegriCell Provides Process Development, <span value="ACORN:3116858326" idsrc="xmltag.org" >Technology Transfer</span>, and Clinical Cryopreservation Services Supporting Verismo's Novel Multi-chain KIR-CAR Programs for Lead Candidates SynKIR™-110 and SynKIR™-310</i></p><p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>June 25, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=1388779963&amp;u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4679950-1%26h%3D3790823054%26u%3Dhttps%253A%252F%252Fcryoportinc.com%252F%26a%3DCryoport%252C%2BInc.&amp;a=Cryoport%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport, Inc.</span></a> (NASDAQ: CYRX) ("<span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport</span>" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that <span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport Systems'</span> IntegriCell^® cryopreservation services have been selected by <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=3704306897&amp;u=https%3A%2F%2Fverismotherapeutics.com%2F&amp;a=Verismo+Therapeutics" target="_blank" rel="nofollow"><span value="ACORN:5021694617" idsrc="xmltag.org" >Verismo Therapeutics</span></a>, a clinical-stage CAR T cell therapy http://www.streetinsider.com/PRNewswire/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html Thu, 25 Jun 2026 08:00:00 -0400 A.31168583 A.35552990 A.39531742 A.50216946 CYRX O.00074346 O.01522978 O.20222297 O.22023464 O.57762027 http://www.streetinsider.com/PRNewswire/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html <div class="xn-content"> <p class="prntac"><i>IntegriCell Provides Process Development, <span value="ACORN:3116858326" idsrc="xmltag.org" >Technology Transfer</span>, and Clinical Cryopreservation Services Supporting Verismo's Novel Multi-chain KIR-CAR Programs for Lead Candidates SynKIR™-110 and SynKIR™-310</i></p><p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>June 25, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=1388779963&amp;u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4679950-1%26h%3D3790823054%26u%3Dhttps%253A%252F%252Fcryoportinc.com%252F%26a%3DCryoport%252C%2BInc.&amp;a=Cryoport%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport, Inc.</span></a> (NASDAQ: CYRX) ("<span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport</span>" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that <span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport Systems'</span> IntegriCell^® cryopreservation services have been selected by <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=3704306897&amp;u=https%3A%2F%2Fverismotherapeutics.com%2F&amp;a=Verismo+Therapeutics" target="_blank" rel="nofollow"><span value="ACORN:5021694617" idsrc="xmltag.org" >Verismo Therapeutics</span></a>, a clinical-stage CAR T cell therapy http://www.streetinsider.com/PRNewswire/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html Thu, 25 Jun 2026 08:00:00 -0400 A.31168583 A.35552990 A.39531742 A.50216946 CYRX O.00074346 O.01522978 O.20222297 O.22023464 O.57762027 http://www.streetinsider.com/PRNewswire/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html <div class="xn-content"> <p class="prntac"><i>IntegriCell Provides Process Development, <span value="ACORN:3116858326" idsrc="xmltag.org" >Technology Transfer</span>, and Clinical Cryopreservation Services Supporting Verismo's Novel Multi-chain KIR-CAR Programs for Lead Candidates SynKIR™-110 and SynKIR™-310</i></p><p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>June 25, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=1388779963&amp;u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4679950-1%26h%3D3790823054%26u%3Dhttps%253A%252F%252Fcryoportinc.com%252F%26a%3DCryoport%252C%2BInc.&amp;a=Cryoport%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport, Inc.</span></a> (NASDAQ: CYRX) ("<span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport</span>" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that <span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport Systems'</span> IntegriCell^® cryopreservation services have been selected by <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=3704306897&amp;u=https%3A%2F%2Fverismotherapeutics.com%2F&amp;a=Verismo+Therapeutics" target="_blank" rel="nofollow"><span value="ACORN:5021694617" idsrc="xmltag.org" >Verismo Therapeutics</span></a>, a clinical-stage CAR T cell therapy http://www.streetinsider.com/PRNewswire/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html Thu, 25 Jun 2026 08:00:00 -0400 A.31168583 A.35552990 A.39531742 A.50216946 CYRX O.00074346 O.01522978 O.20222297 O.22023464 O.57762027 http://www.streetinsider.com/PRNewswire/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html <div class="xn-content"> <p class="prntac"><i>IntegriCell Provides Process Development, <span value="ACORN:3116858326" idsrc="xmltag.org" >Technology Transfer</span>, and Clinical Cryopreservation Services Supporting Verismo's Novel Multi-chain KIR-CAR Programs for Lead Candidates SynKIR™-110 and SynKIR™-310</i></p><p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>June 25, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=1388779963&amp;u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4679950-1%26h%3D3790823054%26u%3Dhttps%253A%252F%252Fcryoportinc.com%252F%26a%3DCryoport%252C%2BInc.&amp;a=Cryoport%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport, Inc.</span></a> (NASDAQ: CYRX) ("<span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport</span>" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that <span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport Systems'</span> IntegriCell^® cryopreservation services have been selected by <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=3704306897&amp;u=https%3A%2F%2Fverismotherapeutics.com%2F&amp;a=Verismo+Therapeutics" target="_blank" rel="nofollow"><span value="ACORN:5021694617" idsrc="xmltag.org" >Verismo Therapeutics</span></a>, a clinical-stage CAR T cell therapy http://www.streetinsider.com/PRNewswire/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html Thu, 25 Jun 2026 08:00:00 -0400 A.31168583 A.35552990 A.39531742 A.50216946 CYRX O.00074346 O.01522978 O.20222297 O.22023464 O.57762027 http://www.streetinsider.com/PRNewswire/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html <div class="xn-content"> <p class="prntac"><i>IntegriCell Provides Process Development, <span value="ACORN:3116858326" idsrc="xmltag.org" >Technology Transfer</span>, and Clinical Cryopreservation Services Supporting Verismo's Novel Multi-chain KIR-CAR Programs for Lead Candidates SynKIR™-110 and SynKIR™-310</i></p><p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>June 25, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=1388779963&amp;u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4679950-1%26h%3D3790823054%26u%3Dhttps%253A%252F%252Fcryoportinc.com%252F%26a%3DCryoport%252C%2BInc.&amp;a=Cryoport%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport, Inc.</span></a> (NASDAQ: CYRX) ("<span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport</span>" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that <span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport Systems'</span> IntegriCell^® cryopreservation services have been selected by <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=3704306897&amp;u=https%3A%2F%2Fverismotherapeutics.com%2F&amp;a=Verismo+Therapeutics" target="_blank" rel="nofollow"><span value="ACORN:5021694617" idsrc="xmltag.org" >Verismo Therapeutics</span></a>, a clinical-stage CAR T cell therapy http://www.streetinsider.com/PRNewswire/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html Thu, 25 Jun 2026 08:00:00 -0400 A.31168583 A.35552990 A.39531742 A.50216946 CYRX O.00074346 O.01522978 O.20222297 O.22023464 O.57762027 http://www.streetinsider.com/PRNewswire/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html <div class="xn-content"> <p class="prntac"><i>IntegriCell Provides Process Development, <span value="ACORN:3116858326" idsrc="xmltag.org" >Technology Transfer</span>, and Clinical Cryopreservation Services Supporting Verismo's Novel Multi-chain KIR-CAR Programs for Lead Candidates SynKIR™-110 and SynKIR™-310</i></p><p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>June 25, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=1388779963&amp;u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4679950-1%26h%3D3790823054%26u%3Dhttps%253A%252F%252Fcryoportinc.com%252F%26a%3DCryoport%252C%2BInc.&amp;a=Cryoport%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport, Inc.</span></a> (NASDAQ: CYRX) ("<span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport</span>" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that <span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport Systems'</span> IntegriCell^® cryopreservation services have been selected by <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=3704306897&amp;u=https%3A%2F%2Fverismotherapeutics.com%2F&amp;a=Verismo+Therapeutics" target="_blank" rel="nofollow"><span value="ACORN:5021694617" idsrc="xmltag.org" >Verismo Therapeutics</span></a>, a clinical-stage CAR T cell therapy http://www.streetinsider.com/PRNewswire/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html Thu, 25 Jun 2026 08:00:00 -0400 A.31168583 A.35552990 A.39531742 A.50216946 CYRX O.00074346 O.01522978 O.20222297 O.22023464 O.57762027 http://www.streetinsider.com/PRNewswire/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html <div class="xn-content"> <p class="prntac"><i>IntegriCell Provides Process Development, <span value="ACORN:3116858326" idsrc="xmltag.org" >Technology Transfer</span>, and Clinical Cryopreservation Services Supporting Verismo's Novel Multi-chain KIR-CAR Programs for Lead Candidates SynKIR™-110 and SynKIR™-310</i></p><p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>June 25, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=1388779963&amp;u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4679950-1%26h%3D3790823054%26u%3Dhttps%253A%252F%252Fcryoportinc.com%252F%26a%3DCryoport%252C%2BInc.&amp;a=Cryoport%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport, Inc.</span></a> (NASDAQ: CYRX) ("<span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport</span>" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that <span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport Systems'</span> IntegriCell^® cryopreservation services have been selected by <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4719425-1&amp;h=3704306897&amp;u=https%3A%2F%2Fverismotherapeutics.com%2F&amp;a=Verismo+Therapeutics" target="_blank" rel="nofollow"><span value="ACORN:5021694617" idsrc="xmltag.org" >Verismo Therapeutics</span></a>, a clinical-stage CAR T cell therapy http://www.streetinsider.com/PRNewswire/Cryoport%27s+IntegriCell%C2%AE+Cryopreservation+Services+Selected+by+Verismo+Therapeutics+to+Support+Clinical+KIR-CAR+T+Cell+Therapy+Programs/26688507.html Thu, 25 Jun 2026 08:00:00 -0400 A.31168583 A.35552990 A.39531742 A.50216946 CYRX O.00074346 O.01522978 O.20222297 O.22023464 O.57762027